

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

THE GROUP'S PRODUCT INSULIN DEGLUDEC AND LIRAGLUTIDE INJECTION MARKETING REGISTRATION APPLICATION BEEN ACCEPTED

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the marketing registration application for Insulin Degludec and Liraglutide Injection ("IDegLira"), self-developed by Zhuhai United Bio-Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, has been accepted by China National Medical Products Administration, with the application acceptance number CXSS2600154. The Company is the first enterprise in China to submit the marketing registration application for IDegLira biosimilar.

IDegLira is a long-acting fixed-dose combination antidiabetic preparation composed of the basal insulin degludec (IDeg) and the glucagon-like peptide-1 (GLP-1) analogue liraglutide. The two components retain their pharmacokinetic profiles within the combination respectively. Through complementary mechanisms and synergistic effects, they overcome the limitations of monotherapy, achieving round-the-clock stable glycemic control and significantly improving glycemic target attainment rates, while also addressing weight management and hypoglycemia risk control — delivering multiple clinical benefits of "lowering blood glucose, stabilizing glycemic levels, and ensuring safe weight control". Compared with monotherapy or combination regimens, this product requires only once-daily subcutaneous injection. While enhancing efficacy and safety, it substantially simplifies the dosing regimen and improves long-term adherence, offering patients with type 2 diabetes a more effective, safer, and more convenient integrated therapeutic option.

This marketing registration application marks another significant achievement for the Company in the field of diabetes treatment. Moving forward, the Company will continue to advance the research and development of new products, strengthen its competitiveness and innovation in the biopharmaceutical industry, and focus on chronic disease treatment by delivering higher-quality products and a robust pipeline to serve clinical practice and benefit patients, which is expected to generate greater value for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 24 September 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.